PARP inhibitors: will the new class of drugs match the hype?

R. Tuma
DOI: https://doi.org/10.1093/jnci/djp315
2009-09-16
Journal of the National Cancer Institute
Abstract:BRCA proteins play a role in DNA repair. Healthy cells have several different DNA repair pathways at their disposal; PARP is required for the base excision repair pathway, which mends single-strand nicks, whereas the BRCA proteins are critical for the homologous recombination pathway, which fi xes double-strand breaks. Cells can survive when one repair system breaks down, but they start to die when two of the DNA repair mechanisms stop functioning. Therefore, the combination of a PARP inhibitor and loss of a functional BRCA protein leads to cell death. Preclinical data suggested that the hypothesis was correct; tumor cells that lacked functional BRCA1 or -2 died in the presence of PARP inhibition in vitro. Researchers found that cells that had one normal BRCA allele and one mutant BRCA allele — which is typical of most cells in an individual who carries a BRCA1 or -2 mutation — tolerate PARP inhibition without a problem. In the tumor cells, however, which have lost their remaining functional BRCA gene, PARP inhibition is toxic.
What problem does this paper attempt to address?